Study on Congenital Immune Dysfunction in Cystic Fibrosis Research Background Cystic Fibrosis (CF) is a genetic disease caused by mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, primarily affecting the lungs and digestive system. One of the major problems faced by CF patients is recurrent infections and inflammatio...

Mechanism Study on 5-Hydroxytryptamine Regulating Histone Modifications to Drive Liver Metastasis Academic Background Cancer metastasis is one of the leading causes of cancer patient mortality, especially visceral organ metastases such as liver metastasis (liver metastasis). Neuroendocrine tumors (NETs) are a class of highly metastatic tumors, amon...

5-HT7R Enhances Neuroimmune Resilience and Alleviates Meningitis by Promoting CCR5 Ubiquitination Academic Background Bacterial meningitis is a rapidly onset, highly fatal disease with epidemic potential, especially when caused by Streptococcus pneumoniae (S.p.) infection. The destruction of the blood-brain barrier (BBB) leads to the release of inf...

Prevalence and Incidence of Comorbidities in Japanese Patients with Dermatologic Diseases Academic Background Dermatologic diseases such as atopic dermatitis (AD), psoriasis, alopecia areata (AA), and vitiligo are common chronic inflammatory or autoimmune skin disorders. These conditions not only significantly impact patients’ quality of life but a...

The Impact of Antibiotic Therapy on Psoriasis Patients with Streptococcal Infection Academic Background Psoriasis is a chronic, relapsing inflammatory systemic skin disease with a global prevalence of around 2%-3%. Although its pathogenesis is not fully understood, studies suggest that bacterial, viral, and fungal infections may induce or exacerbat...

Academic Background Pemphigus Vulgaris (PV) is a rare and severe autoimmune blistering disease characterized by a chronic course accompanied by multiple complications and side effects from medication. Currently, guidelines in many countries recognize systemic corticosteroids (CS) and rituximab (RTX) as first-line treatments for PV. However, due to ...